Alkermes plc. Inventory, Finished Goods, Net of Reserves
Alkermes plc. (ALKS) had Inventory, Finished Goods, Net of Reserves of $119.65 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-07-28
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $119.65M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $144.89M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $37.74M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $35.36M.
| Period end | Inventory, Finished Goods, Net of Reserves |
|---|---|
| 2026-06-30 | $119.65M 10-Q · filed 2026-07-28 |
| 2026-03-31 | $144.89M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $37.74M 10-Q · filed 2026-07-28 |
| 2025-09-30 | $35.36M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $42.11M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $39.55M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $30.88M 10-K · filed 2026-02-25 |
| 2024-09-30 | $35.74M 10-Q · filed 2024-10-24 |
| 2024-06-30 | $49.52M 10-Q · filed 2024-07-24 |
| 2024-03-31 | $49.29M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $46.15M 10-K · filed 2025-02-12 |
| 2023-09-30 | $50.41M 10-Q · filed 2023-10-25 |
| 2023-06-30 | $52.57M 10-Q · filed 2023-07-26 |
| 2023-03-31 | $51.28M 10-Q · filed 2023-04-26 |
| 2022-12-31 | $44.13M 10-K · filed 2024-02-21 |
| 2022-09-30 | $28.59M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $32.30M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $38.97M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $35.10M 10-K · filed 2023-02-16 |
| 2021-09-30 | $41.55M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $34.03M 10-Q · filed 2021-07-28 |
| 2021-03-31 | $30.31M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $27.55M 10-K · filed 2022-02-16 |
| 2020-09-30 | $27.32M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $30.47M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $22.40M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $13.16M 10-K · filed 2021-02-11 |
| 2019-09-30 | $18.34M 10-Q · filed 2019-10-23 |
| 2019-06-30 | $18.22M 10-Q · filed 2019-07-25 |
| 2019-03-31 | $17.79M 10-Q · filed 2019-04-25 |
| 2018-12-31 | $20.35M 10-K · filed 2020-02-13 |
| 2018-09-30 | $23.29M 10-Q · filed 2018-10-23 |
| 2018-06-30 | $18.66M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $20.98M 10-Q · filed 2018-04-26 |
| 2017-12-31 | $24.43M 10-K · filed 2019-02-15 |
| 2017-09-30 | $29.48M 10-Q · filed 2017-10-26 |
| 2017-06-30 | $23.29M 10-Q · filed 2017-07-27 |
| 2017-03-31 | $18.51M 10-Q · filed 2017-04-27 |
| 2016-12-31 | $21.77M 10-K · filed 2018-02-16 |
| 2016-09-30 | $19.36M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $17.11M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $13.34M 10-Q · filed 2016-04-28 |
| 2015-12-31 | $9.54M 10-K · filed 2017-02-17 |
| 2015-09-30 | $10.11M 10-Q · filed 2015-10-29 |
| 2015-06-30 | $11.77M 10-Q · filed 2015-07-30 |
| 2015-03-31 | $14.61M 10-Q · filed 2015-04-30 |
| 2014-12-31 | $15.43M 10-K · filed 2016-02-25 |
| 2014-09-30 | $7.77M 10-Q · filed 2014-10-29 |
| 2014-06-30 | $18.41M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $15.08M 10-Q · filed 2014-04-30 |
| 2013-12-31 | $12.23M 10-K · filed 2015-02-24 |
| 2013-09-30 | $12.88M 10-Q · filed 2013-10-31 |
| 2013-06-30 | $13.47M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $16.14M 10-KT · filed 2014-02-27 |
| 2012-12-31 | $21.32M 10-Q · filed 2013-01-31 |
| 2012-09-30 | $17.63M 10-Q · filed 2012-11-01 |
| 2012-06-30 | $19.17M 10-Q · filed 2012-07-26 |
| 2012-03-31 | $16.97M 10-K · filed 2013-05-23 |
| 2011-03-31 | $11.13M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |